Physician profile
John Hoffman
NPI 1861498503
$9,731.62
in general payments reported to CMS, 2019-2025
56 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $768 · 2021: $1,444 · 2022: $1,249 · 2023: $1,711 · 2024: $1,637 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.65 | 2019-2025 | |
| Pfizer INC. | $792.36 | 2019-2025 | |
| Novo Nordisk INC | $766.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $741.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $605.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $551.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $481.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $397.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.30 | 2019-2024 | Trintellix |
| Abbott Laboratories | $269.63 | 2021-2025 | Freestyle Libre, Proclaim |
| Corium, LLC | $255.51 | 2022-2024 | Azstarys |
| Astellas Pharma US INC | $225.00 | 2019-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $223.11 | 2020-2023 | Qelbree, Xyosted |
| Amarin Pharma, INC. | $211.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.21 | 2019-2025 | Jardiance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.